Bortezomib beats standard therapy in relapsed multiple myeloma

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1444, 2004-01, pp. : 13-14

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bortezomib in multiple myeloma

By Terpos Evangelos Roussou Maria Dimopoulos Meletios-Athanassios

Expert Opinion on Drug Metabolism and Toxicology, Vol. 4, Iss. 5, 2008-05 ,pp. : 639-654

Informa Healthcare

Access to resources Recommend Favorite

Bortezomib for multiple myeloma

By Popat Rakesh Joel Simon Oakervee Heather Cavenagh Jamie

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 10, 2006-07 ,pp. : 1337-1346

Informa Healthcare

Access to resources Recommend Favorite

Bortezomib continues to demonstrate superiority over high-dose dexamethasone in patients with relapsed multiple myeloma

Inpharma, Vol. 1, Iss. 1621, 2008-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Results of the first bortezomib-based induction therapy in the treatment of multiple myeloma

By Kortüüm Martin Einsele Hermann

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 10, 2011-07 ,pp. : 1661-1663

Informa Healthcare

Access to resources Recommend Favorite

Carfilzomib: In Relapsed, or Relapsed and Refractory, Multiple Myeloma

By McCormack Paul L.

Drugs, Vol. 72, Iss. 15, 2012-10 ,pp. : 2023-2032

Adis International

Access to resources Recommend Favorite